Semaglutide works for 87% of patients — but if you're not seeing results, it's almost never random. Here are the 7 most common clinical reasons semaglutide underperforms, and exactly what to do about each.
If you've been on semaglutide for more than 8 weeks and aren't seeing meaningful results, you're frustrated — and you deserve a specific answer, not a shrug. "It works differently for everyone" is not useful clinical guidance.
The reality: semaglutide produces at least 5% body weight loss in 87% of patients in the STEP trials. When it's not working, there's almost always a specific identifiable reason. Here are the 7 most common ones.
The single most common reason semaglutide "isn't working" is that patients are still on 0.25mg — the starting dose designed for tolerance building, not weight loss. At 0.25mg, most patients experience little to no appetite suppression. The STEP trials didn't show significant weight loss until participants reached 0.5mg and above.
What to do: Check your current dose against our dose tracker. If you're in weeks 1–4, the medication is working exactly as designed — meaningful results start at week 5 when the dose increases.
Semaglutide's dose-response relationship is significant — higher doses produce more weight loss. The STEP trials showed average 15% body weight loss at 2.4mg. Patients who plateau or see limited results at 0.5mg or 1mg frequently see renewed progress when titrating to higher doses.
What to do: Discuss titration with your physician. If you've been at 0.5mg for more than 8 weeks without significant progress, the next step is usually 1mg, then 1.7mg, then 2.4mg.
A 2025 study in the journal Menopause found women on HRT lost approximately 30% more weight on semaglutide than women not on HRT. Estrogen decline creates insulin resistance that directly reduces GLP-1 receptor sensitivity. Semaglutide is fighting against the hormonal environment instead of working with it.
What to do: If you're perimenopausal or postmenopausal, get a comprehensive hormone evaluation. Addressing estrogen deficiency alongside semaglutide is the most evidence-based approach for women 40+ who are underperforming on GLP-1 therapy. Our free hormone map can identify which hormones are involved.
GLP-1 medications suppress appetite so powerfully that many patients accidentally eat 600–800 calories per day. At that level, the body breaks down muscle as fast as fat — or faster. Muscle loss reduces resting metabolic rate, which eventually stalls or stops weight loss even with continued medication.
What to do: Track protein, not calories. Target 0.7–1g per pound of bodyweight. Add resistance training 2–3x per week. If you're losing more than 2 lbs/week, you're likely in too deep a deficit and losing muscle.
Semaglutide works primarily through GLP-1 receptors. If you have significant insulin resistance — from PCOS, prediabetes, metabolic syndrome, or estrogen decline — semaglutide's appetite suppression may work, but fat release from cells is blocked by chronically elevated insulin. You feel less hungry but still can't lose fat efficiently.
What to do: Consider switching to tirzepatide, which activates GIP receptors in addition to GLP-1 — directly addressing insulin resistance. Tirzepatide produces 47% more weight loss than semaglutide in direct comparison (SURMOUNT-5). Additionally, reduce refined carbohydrates, increase protein, and consider a fasting insulin test to confirm insulin resistance.
Subcutaneous injection into incorrect tissue — injecting into muscle rather than fat — significantly affects absorption. Semaglutide must be injected into subcutaneous fat (abdomen, thigh, or upper arm). Muscle injection produces faster and lower peak absorption, reducing effectiveness.
What to do: Review our injection guide. Pinch the skin before injecting. Use the full needle depth. Rotate injection sites. Do not inject into areas with scar tissue or bruising.
After 6–12 months on semaglutide at maximum dose, many patients plateau — the body adapts to the medication. This isn't failure; it's biology. The most evidence-based next step is switching to tirzepatide.
What to do: Read our full plateau guide. The short version: switch to tirzepatide (different mechanism, frequently restarts progress), increase resistance training to rebuild metabolic rate, and evaluate whether hormonal factors are contributing.
Tirzepatide's dual GLP-1 + GIP mechanism addresses several of the most common reasons semaglutide underperforms — particularly insulin resistance. DirectMeds offers physician-supervised compounded tirzepatide from $149/month.
Check tirzepatide eligibility at DirectMeds →